Shenma Medical Group General Hospital Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Pingdingshan Henan China

Organization Overview

First Clinical Trial
2015
NCT02621333
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shenma Medical Group General Hospital

Active Ingredients

Drugs in Phase 3 Trials (2)

arginine (1 trial)

trimetazidine (1 trial)

Drugs in Phase 2 Trials (1)

cytokine induced killer cells (1 trial)

Drugs in Other Trials (4)

heparin (liquaemin) (2 trials)

nitroprusside (nipride) (2 trials)

sodium chloride (2 trials)

tirofiban (aggrastat) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 7